About CellCentric

CellCentric develops inobrodib, an oral first-in-class small molecule inhibitor targeting the twin proteins p300 and CBP. By binding to their bromodomain, inobrodib disrupts cancer cell growth by reducing expression of genes like MYC and IRF4 that drive tumour progression. The drug is being evaluated in clinical trials for multiple myeloma and other specific cancers. Many new cancer treatments require significant hospitalisation. InoPd, inobrodib combined with standard backbone therapies, is designed for community settings, reducing healthcare burden while reaching wider patient populations. Oral delivery gives patients greater control over their treatment, addressing a key patient preference while maintaining clinical effectiveness.